Click here for slides on this topic


VLDL-C

Abbreviation for very low-density lipoprotein-cholesterol.


The following content matched the glossary term: VLDL-C

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

Glycemic Control: How Low Should You Go?

Top

Glycemic Control: How Low Should You Go? NDEI Education Council Co-Chair Burton E. Sobel, MD, provides expert commentary on the debate over intensive versus somewhat less intensive glycemic control in the context of a recent study by Zhao et al assessing the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk in type 2 diabetes

Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes

Top

Cohen LB, Taviera TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011 Oct 21. [Epub ahead of print]. To assess whether VA MEDIC-E (Veterans Affairs Multi-disciplinary Education and Diabetes Intervention for Cardiac risk reduction— Extended for 6 months), a pharmacist-led shared medical appointments program, could improve attainment of target goals for hypertension, hyperglycemia, hyperlipidemia, and tobacco use in patients with type 2 diabetes compared to standard primary care after 6 months of intervention.

Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus

Top

Ai M, Otokozawa S, Schaefer EJ, et al. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin Chimica Acta.. 2009;406(1-2):71-74. Diabetes mellitus is a major risk factor for coronary heart disease (CHD), renal failure, retinopathy, and neuropathy. Lowering glycosylated hemoglobin (HbA1c) as well as low-density lipoprotein-cholesterol (LDL-C) has been associated with a decreased risk of these complications.

Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus

Top

Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother. 2009;10(12):1875-1882. The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients.

Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus

Top

Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism. 2009;58(6):739-745. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, not only improves insulin resistance and glycemic control, but may also have additional beneficial vascular effects in patients with type 2 diabetes mellitus.

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER

Top

Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the US. J Am Coll Cardiol. 2009;53(11):931-935. We assessed the prevalence of low-density lipoprotein-cholesterol (LDL-C) <130 mg/dl with elevated high-sensitivity C-reactive protein (hsCRP) in the National Health And Nutrition Examination Survey (NHANES), weighted to be representative of the general U.S. population.

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006

Top

Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443-453. Changes in the prevalence, treatment, and management of diabetes in the United States from 1999 to 2006 were studied using data from the National Health and Nutrition Examination Survey.

Relationship between changes in insulin sensitivity & associated CVD risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals

Top

Abbasi F, Lima NK, Reaven GM. Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Metabolism. 2009;58(3):373-378. This study compared the effects of administering rosiglitazone (RSG) vs pioglitazone (PIO) on cardiovascular disease risk factors in insulin-resistant, nondiabetic individuals with no apparent disease.

Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin

Top

Derosa G, D'Angelo A, Fogari E, et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther. 2009;34(1):13-23. Most antidiabetic agents target only one of several underlying causes of diabetes. The complementary actions of the glinides and the biguanides may give optimal glycemic control in patients with type 2 diabetes mellitus.

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: VLDL-C Slides Found: 9
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis
Non–HDL-C as a Predictor of Risk for CHD in Diabetes
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI